Matches in Nanopublications for { ?s ?p "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP554392.RAW3HxYjUIDJwKFvWetQZzb9lKO-hOZeTPa9SHkXVhTuc130_assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP554392.RAW3HxYjUIDJwKFvWetQZzb9lKO-hOZeTPa9SHkXVhTuc130_provenance.
- NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP803122.RAbGMtEDWf3nMDQqdY3XZbDIp9_ByuhM8ZPYyPIh_58XI130_provenance.
- assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1154265.RAfrRyZjlZNB8u-kor5gX0s4pg4YIVVklAii78-up_cpw130_assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1154265.RAfrRyZjlZNB8u-kor5gX0s4pg4YIVVklAii78-up_cpw130_provenance.
- NP1154267.RAYzJVHnOY9qyv9UtTtIKBln_lZk4s2wQwMezQflPolM4130_assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1154267.RAYzJVHnOY9qyv9UtTtIKBln_lZk4s2wQwMezQflPolM4130_provenance.
- NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_provenance.
- NP1154269.RAiQRcumQ1SZ6CP_JkA-zOCwwdug50VSHzXh15rjyQkPk130_assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1154269.RAiQRcumQ1SZ6CP_JkA-zOCwwdug50VSHzXh15rjyQkPk130_provenance.
- NP1154273.RArlEUZbL2Fuz9xA2iWeeQvm20xCxEUzOvGPCG1TVvXw8130_assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1154273.RArlEUZbL2Fuz9xA2iWeeQvm20xCxEUzOvGPCG1TVvXw8130_provenance.
- NP1154274.RAlDbfq268-3mJNIS-LmCjqPYg8lYTz3ASSRXwj8qGHz8130_assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1154274.RAlDbfq268-3mJNIS-LmCjqPYg8lYTz3ASSRXwj8qGHz8130_provenance.
- NP946065.RAwN31S8KTE8G-B2zDcWl9JOGdZ9Mnm966dhFLJZrOjI4130_assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP946065.RAwN31S8KTE8G-B2zDcWl9JOGdZ9Mnm966dhFLJZrOjI4130_provenance.